Drug Trial Radar · NCT02006472
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Last checked: Nov 19, 2026Latest source record: Jul 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
408
Actual
Start
Feb 28, 2014
Primary completion
Dec 16, 2015
Study completion Jul 7, 2016
Sponsor
- Lead sponsor
- PrileniaIndustry
- Sponsor type
- Industry
- Collaborators
- European Huntington's Disease Network; Huntington Study Group
- First posted
- Dec 10, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, multinational, randomized, parallel-group, double-blind, placebo-controlled, dose range finding study to compare the efficacy and safety of different doses of pridopidine versus placebo in the treatment of motor impairment in Huntington's Disease (HD).
Conditions
- Huntington's Disease
Interventions
PridopidineDrug
22.5 mg and 45 mg capsules
PlaceboOther
Capsules matching drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) at Week 26Time frame: 26 weeks
Locations
58 sites in 12 countries. Site status is shown where the registry gives one.
Investigational Site 12199
La Jolla, California
Investigational Site 12204
Los Angeles, California
Investigational Site 12201
Englewood, Colorado
Investigational Site 12196
Washington D.C., District of Columbia
Investigational Site 12207
Chicago, Illinois
Investigational Site 12202
Baltimore, Maryland
Investigational Site 12206
Baltimore, Maryland
Investigational Site 12200
Manhasset, New York
Investigational Site 12203
New York, New York
Investigational Site 12198
Rochester, New York
Investigational Site 12211
Winston-Salem, North Carolina
Investigational Site 12205
Cincinnati, Ohio
Investigational Site 12209
Pittsburgh, Pennsylvania
Investigational Site 12208
Salt Lake City, Utah
Investigational Site 12210
Richmond, Virginia
Investigational Site 12197
Kirkland, Washington
Investigational Site 78055
Caulfield South, Australia
Investigational Site 78056
Kew, Australia
Investigational Site 78058
Subiaco, Australia
Investigational Site 78057
Westmead, Australia
Investigational Site 33021
Innsbruck, Austria
Investigational Site 33027
Vienna, Austria
Investigational Site 11035
Vancouver, British Columbia, Canada
Investigational Site 11037
Ottawa, Ontario, Canada
Investigational Site 11036
Toronto, Ontario, Canada
Investigational Site 39028
Aarhus, Denmark
Investigational Site 39027
Copenhagen, Denmark
Investigational Site 35123
Angers, France
Investigational Site 35122
Créteil, France
Investigational Site 35125
Lille, France
Investigational Site 35124
Marseille, France
Investigational Site 35121
Salouël, France
Investigational Site 35165
Toulouse, France
Investigational Site 32408
Berlin, Germany
Investigational Site 32410
Bochum, Germany
Investigational Site 32409
Münster, Germany
Investigational Site 32407
Ulm, Germany
Investigational Site 30083
Florence, Italy
Investigational Site 30080
Milan, Italy
Investigational Site 30082
Naples, Italy
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.